Long-term Safety, Tolerability, and Efficacy of Efgartigimod in Patients WithGeneralized Myasthenia Gravis: interim Results of the ADAPT+ Study

Authors
Category Primary study
ConferenceActa myologica
Year 2022
This article has no abstract
Epistemonikos ID: 697c02f8d6de2d9b6798d91336b3076ea9cf908f
First added on: Mar 10, 2026